ror1 inhibitor ari 1 Search Results


small molecule inhibitors kan0441571c  (Kancera AB)
90
Kancera AB small molecule inhibitors kan0441571c
Potential conjugation strategies of the three anti-ROR1 <t>ADCs.</t> ( A ) NBE-002, a homologous ADC generated by Sortase A-mediated SMAC-technology™ to attach Gly ( n ) -EDA-PNU-159682 to a humanized antibody. ( B ) VelosBio101, a humanized antibody coupled with MMAE via the ‘MC-VC-PABC’ linker. ( C ) LCB71/ABL202, a homologous ADC produced by Farnesyltransferase-mediated ConjuALL™ to introduce geranyl ketone pyrophosphate (GKPP) to a human antibody and subsequent oxime ligation reaction to load the dPBD prodrug.
Small Molecule Inhibitors Kan0441571c, supplied by Kancera AB, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ror1+inhibitor+ari+1/kan0441571c/pmc08597957-82-6-15
Average 90 stars, based on 1 article reviews
small molecule inhibitors kan0441571c - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Potential conjugation strategies of the three anti-ROR1 ADCs. ( A ) NBE-002, a homologous ADC generated by Sortase A-mediated SMAC-technology™ to attach Gly ( n ) -EDA-PNU-159682 to a humanized antibody. ( B ) VelosBio101, a humanized antibody coupled with MMAE via the ‘MC-VC-PABC’ linker. ( C ) LCB71/ABL202, a homologous ADC produced by Farnesyltransferase-mediated ConjuALL™ to introduce geranyl ketone pyrophosphate (GKPP) to a human antibody and subsequent oxime ligation reaction to load the dPBD prodrug.

Journal: Antibody Therapeutics

Article Title: Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers

doi: 10.1093/abt/tbab023

Figure Lengend Snippet: Potential conjugation strategies of the three anti-ROR1 ADCs. ( A ) NBE-002, a homologous ADC generated by Sortase A-mediated SMAC-technology™ to attach Gly ( n ) -EDA-PNU-159682 to a humanized antibody. ( B ) VelosBio101, a humanized antibody coupled with MMAE via the ‘MC-VC-PABC’ linker. ( C ) LCB71/ABL202, a homologous ADC produced by Farnesyltransferase-mediated ConjuALL™ to introduce geranyl ketone pyrophosphate (GKPP) to a human antibody and subsequent oxime ligation reaction to load the dPBD prodrug.

Article Snippet: In addition to naked antibodies and ADCs, small molecule inhibitors (e.g. KAN0439834 and KAN0441571C by Kancera, DB03208, strictinin, ARI-1), bispecific antibodies (e.g. NVG-111 by Novalgen) and CAR-Ts (e.g. Cirtuzumab-based CAR-T by Oncternal Therapeutics and JCAR-024 by Juno Therapeutics) have been developed to target ROR1 [ , , ].

Techniques: Conjugation Assay, Generated, Produced, Introduce, Ligation